Cargando…

Immune modulation for cancer therapy

BACKGROUND: Immune modulation in cancer refers to a range of treatments aimed at harnessing a patient's immune system to achieve tumour control, stabilisation, and potential eradication of disease. A novel therapeutic drug class called immune checkpoint-blocking antibodies modulate T-cell pathw...

Descripción completa

Detalles Bibliográficos
Autores principales:	Naidoo, J, Page, D B, Wolchok, J D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2014
Materias:	Minireview
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4264429/ https://www.ncbi.nlm.nih.gov/pubmed/25211661 http://dx.doi.org/10.1038/bjc.2014.348

Ejemplares similares

Hiding the road signs that lead to tumor immunity
por: Schaer, David A., et al.
Publicado: (2011)

T-regulatory cell modulation: the future of cancer immunotherapy?
por: Nizar, S, et al.
Publicado: (2009)

The state of the art: immune-mediated mechanisms of monoclonal antibodies in cancer therapy
por: Griggs, J, et al.
Publicado: (2009)

Intensity-modulated radiation therapy: emerging cancer treatment technology
por: Hong, T S, et al.
Publicado: (2005)

Targeting HSP90 for cancer therapy
por: Mahalingam, D, et al.
Publicado: (2009)

Innate immune recognition and modulation in hepatitis D virus infection
por: Jung, Stephanie, et al.
Publicado: (2020)

Faecal microbiota transplantation enhances efficacy of immune checkpoint inhibitors therapy against cancer
por: Kang, Yong-Bo, et al.
Publicado: (2021)

Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer
por: Michelakis, E D, et al.
Publicado: (2008)

Engineering T cells for cancer therapy
por: Mansoor, W, et al.
Publicado: (2005)

Endocrine therapy in prostate cancer: time for reappraisal of risks, benefits and cost-effectiveness?
por: Bourke, L, et al.
Publicado: (2013)

Sliding set-points of immune responses for therapy of autoimmunity
por: Hsieh, Chyi-Song, et al.
Publicado: (2010)

When less may be more: calorie restriction and response to cancer therapy
por: O’Flanagan, Ciara H., et al.
Publicado: (2017)

Mechanisms of adverse effects of anti-VEGF therapy for cancer
por: Kamba, T, et al.
Publicado: (2007)

Targeted and immune therapies for hepatocellular carcinoma: Predictions for 2019 and beyond
por: Kudo, Masatoshi
Publicado: (2019)

Targeting glucose metabolism for cancer therapy
por: Hamanaka, Robert B., et al.
Publicado: (2012)

Aspirin and cancer: has aspirin been overlooked as an adjuvant therapy?
por: Langley, R E, et al.
Publicado: (2011)

Molecular characterisation of cutaneous melanoma: creating a framework for targeted and immune therapies
por: Rajkumar, Shivshankari, et al.
Publicado: (2016)

Angiogenesis and immune checkpoint dual blockade: Opportunities and challenges for hepatocellular carcinoma therapy
por: Li, Si-Qi, et al.
Publicado: (2022)

Tumor microenvironments, the immune system and cancer survival
por: Strausberg, Robert L
Publicado: (2005)

Multiparametric analysis of colorectal cancer immune responses
por: Leman, Julia KH, et al.
Publicado: (2018)

Immune aspects of hepatocellular carcinoma: From immune markers for early detection to immunotherapy
por: Mattos, Ângelo Z, et al.
Publicado: (2021)

Proton beam therapy and localised prostate cancer: current status and controversies
por: Efstathiou, J A, et al.
Publicado: (2013)

Tissue-selective therapy of cancer
por: Blagosklonny, M V
Publicado: (2003)

Immune evasion mechanisms and therapeutic strategies in gastric cancer
por: Ma, En-Si, et al.
Publicado: (2022)

Interrogating the interplay of angiogenesis and immunity in metastatic colorectal cancer
por: Kampoli, Katerina, et al.
Publicado: (2022)

Impact of microbiota-immunity axis in pancreatic cancer management
por: Bartolini, Ilenia, et al.
Publicado: (2022)

Targeted anti-vascular therapies for ovarian cancer: current evidence
por: Hall, M, et al.
Publicado: (2013)

The measurement and therapeutic implications of circulating tumour cells in breast cancer
por: Smerage, J B, et al.
Publicado: (2006)

Neoadjuvant therapy for pancreatic ductal adenocarcinoma: Opportunities for personalized cancer care
por: Hamad, Ahmad, et al.
Publicado: (2021)

Adjuvant chemotherapy and HER-2-directed therapy for early-stage breast cancer in the elderly
por: Sun, J, et al.
Publicado: (2017)

Mathematical models of targeted cancer therapy
por: Abbott, L H, et al.
Publicado: (2006)

Control of oncogenesis and cancer therapy resistance
por: Perona, R, et al.
Publicado: (2004)

Targeting TNF-α for cancer therapy
por: Burton, Elizabeth R, et al.
Publicado: (2009)

Neoadjuvant therapy for resectable pancreatic cancer
por: Rahman, Sheikh Hasibur, et al.
Publicado: (2017)

Nanotechnology in diagnosis and therapy of gastrointestinal cancer
por: Liang, Meng, et al.
Publicado: (2022)

HYPE or HOPE: the prognostic value of infiltrating immune cells in cancer
por: Barnes, Tristan A, et al.
Publicado: (2017)

Targeting pancreatic cancer immune evasion by inhibiting histone deacetylases
por: Sim, Wynne, et al.
Publicado: (2022)

New perspectives on molecular targeted therapy in ovarian clear cell carcinoma
por: Tan, D S P, et al.
Publicado: (2013)

Humoral Immunity to Hantavirus Infection
por: Engdahl, Taylor B., et al.
Publicado: (2020)

Hypoxia inducible factors in cancer stem cells
por: Heddleston, J M, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_mtg2l0pv9u3nmrn31422bgvi34